Stents Branch Out and Return to Their Start-Up Roots
While innovation in interventional cardiology has historically come from small companies, industry consolidation and a flattening of technology has, in recent years, given the edge to large suppliers, which now all but dominate the field.
Drug-eluting stents, which require huge resource expenditures, seem to epitomize this shift of interventional cardiology to a big-company game.
But in at least one highly promising area--bifurcated lesions--small companies continue to have the edge in developing a device to effectively treat this significant unmet clinical need.
Encouraging for these smaller companies is the fact that the critical technology hurdle in treating bifurcations is primarily mechanical, not biological, enabling new approaches that can potentially complement, not compete against, drug-coated stents.
by Stephen Levin
Although it's only been a couple of years since the spectacular first clinical results of drug-eluting stents (DES) were reported...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.